Clinical transformation of personalized neoantigen vaccine: opportunities and challenges
10.3872/j.issn.1007-385x.2019.01.004
- VernacularTitle:个体化新抗原疫苗临床转化的机遇与挑战
- Author:
ZHOU Weijun
1
;
LI Yuhua
1
Author Information
1. (Department of Hematology, Zhujiang Hospital of Southern Medical University
- Publication Type:Journal Article
- Keywords:
tumor；immunotherapy;
neoantigen;
vaccine;
precision medicine;
specific T cell
- From:
Chinese Journal of Cancer Biotherapy
2019;26(1):16-21
- CountryChina
- Language:Chinese
-
Abstract:
As one of the pivotal immunotherapies, tumor vaccine has increasingly shown its benefits in the treatment of malignant tumors. However, traditional vaccines targeting tumor associated antigen (TAA) are difficult to be promoted on a large scale in clinic, due to immune tolerance and the risk of inducing autoimmune disease. Neoantigen, which doesn’t present in normal cells and originates from tumor somatic mutations, is considered as ideal target for vaccines recently. Personalized neoantigen vaccine developed on the basis of sequencing, which specifically targets neoantigens, is expected to become an important breakthrough in precision medicine of cancer. This paper will elaborate on the concept, characteristics, preparation process and clinical trials of personalized neoantigen vaccine, and we will also discuss the opportunities and challenges that might be encountered during its clinical transformation.
- Full text:20190104.pdf
